CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K_d values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer.

CTX-471 (5-500 nM) has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with K_d values of 50 nM, 61 nM and 748 nM, respectively.
CTX-471 binds to a unique epitope on CD137.
CTX-471 (0.1-100 nM; 1, 10 μg/mL; 3 days) increases IFN-y production by human T cells in an Fcy receptor-dependent (FcyR-dependent) manner in vitro.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

CTX-471 (i.p.; 150 μg) exhibits curative monotherapy activity in various syngeneic tumor models and shows a unique ability to cure mice of very large tumors. CTX-471 (i.v.; 10-80 mg/kg; on days 0, 7, 14, and 21) is well tolerated, with no signs of hepatic toxicity in high doses.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

CTX-471 (i.p.; 150 μg) exhibits curative monotherapy activity in various syngeneic tumor models and shows a unique ability to cure mice of very large tumors. CTX-471 (i.v.; 10-80 mg/kg; on days 0, 7, 14, and 21) is well tolerated, with no signs of hepatic toxicity in high doses.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Ugur Eskiocak, et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020 Mar 12;5(5):e133647.  [Content Brief]